Biotest AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biotest AG with three other
companies in this sector in GERMANY :
sales of 500.92 million Euro [US$610.14 million]
of which 75%
was EVT Execute),
Eckert & Ziegler Strahlen- und Medizinte
(176.14 million Euro [US$214.54 million]
of which 51%
was Isotope Products), and
Dermapharm Holding SE
(793.83 million Euro [US$966.91 million]
of which 59%
was Pharmaceuticals and other products).
During the first
quarter of 2021, sales at Biotest AG totalled
120.00 million Euro.
an increase of 22.8%
from the 97.70 million Euro in sales at the company during the first quarter of 2020.
During the previous 8 quarters, sales at Biotest AG have increased compared with the same quarter in the previous year.
During the year ended December of 2020, sales at
Biotest AG were 484.20 million Euro (US$589.77 million).
increase of 15.5%
versus 2019, when the company's sales were 419.10 million Euro.
This was the third consecutive year of growth at Biotest AG.
Sales of Plasma and Services saw an increase
18.2% in 2020, from
39.50 million Euro to 46.70 million Euro.
Not all segments of Biotest AG experienced an increase in sales in 2020:
sales of Other fell 9.1% to 7.00 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).